Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.

  title={Methamphetamine-related psychiatric symptoms and reduced brain dopamine transporters studied with PET.},
  author={Yoshimoto Sekine and Masaomi Iyo and Yasuomi Ouchi and Tsutomu Matsunaga and Hideo Tsukada and Hiroyuki Okada and Etsuji Yoshikawa and Masami Futatsubashi and Noriko Takei and N. Mori},
  journal={The American journal of psychiatry},
  volume={158 8},
  • Y. Sekine, M. Iyo, N. Mori
  • Published 1 August 2001
  • Psychology, Medicine, Biology
  • The American journal of psychiatry
OBJECTIVE A positron emission tomography (PET) study has suggested that dopamine transporter density of the caudate/putamen is reduced in methamphetamine users. The authors measured nucleus accumbens and prefrontal cortex density, in addition to caudate/putamen density, in methamphetamine users and assessed the relation of these measures to the subjects' clinical characteristics. METHOD PET and 2-beta-carbomethoxy-3beta-(4-[(11)C] fluorophenyl)tropane, a dopamine transporter ligand, were used… 

Association of dopamine transporter loss in the orbitofrontal and dorsolateral prefrontal cortices with methamphetamine-related psychiatric symptoms.

Dopamine transporter density in the three regions studied was significantly lower in the methamphetamine users than in the comparison subjects and the lower dopamine transporter density was significantly correlated with the duration of methamphetamine use and the severity of psychiatric symptoms.

Dopamine Transporter Density of the Basal Ganglia Assessed with I-123 IPT SPECT in Methamphetamine Abusers

D dopamine transporter imaging using I-123 IPT SPECT may be used to evaluate dopaminergic system of the basal ganglia and the clinical status in methamphetamine abusers to suggest the DAT may be a sensitive and selective indicator of neurotoxic change by the drug.

Structural and metabolic brain changes in the striatum associated with methamphetamine abuse.

Brain structural, chemical and metabolic brain changes, particularly those in the basal ganglia, in individuals who used methamphetamine and in children with prenatal methamphetamine exposure are reviewed, demonstrating abnormalities in brain structure and chemistry convincingly.

Metabolite Alterations in Basal Ganglia Associated with Methamphetamine-related Psychiatric Symptoms: A Proton MRS Study

Cognitive function and nigrostriatal markers in abstinent methamphetamine abusers

Failure to find more substantial changes in transporter levels and neurocognitive function may be attributed to the length of time that MA users were abstinent, although there were no correlations with length of abstinence.

Brain serotonin transporter density and aggression in abstinent methamphetamine abusers.

Protracted abuse of methamphetamine may reduce the density of the serotonin transporter in the brain, leading to elevated aggression, even in currently abstinent abusers.

Brain serotonin transporter in human methamphetamine users

The data suggest that MA might modestly damage brain serotonin neurones and/or inhibit SERT protein expression, with cerebral cortex being more affected than sub-cortical regions.


A long-term abuse of methamphetamine causes psychiatric symptoms, such as psychosis and anxiety disorder-like symptoms. Some of the symptoms are persistent for long time of period even after

Neuromechanism of Developing Methamphetamine Psychosis: A Neuroimaging Study

It is suggested that long‐term use of MAP causes abnormal cerebral blood flow patterns, reduction of brain dopamine transporter density, and metabolite alteration, which may be closely related to a susceptibility to MAP psychosis.



Reduced Striatal Dopamine Transporter Density in Abstinent Methamphetamine and Methcathinone Users: Evidence from Positron Emission Tomography Studies with [11C]WIN-35,428

Persistent reductions in DAT density in methamphetamine and methcathinone users are suggestive of loss of DAT or loss of DA terminals and raise the possibility that as these individuals age, they may be at increased risk for the development of parkinsonism or neuropsychiatric conditions in which brain DA neurons have been implicated.

Striatal dopamine nerve terminal markers in human, chronic methamphetamine users

The found reduced levels of three dopamine nerve terminal markers in post–mortem striatum of chronic methamphetamine users suggest that chronic exposure to methamphetamine does not cause permanent degeneration of striatal dopamine nerve terminals at the doses used by the young subjects in this study.

Dopamine transporters decrease with age.

  • N. VolkowY. Ding R. Gur
  • Medicine, Biology
    Journal of nuclear medicine : official publication, Society of Nuclear Medicine
  • 1996
A 6.6% decrease per decade of life in striatal dopamine transporters of healthy volunteers is recorded in right-handed healthy volunteers.

Prediction of detached personality in healthy subjects by low dopamine transporter binding.

Age-corrected dopamine transporter binding in the putamen, but not in the caudate, correlated negatively with detachment personality scores, especially in the right hemisphere, which supports the hypothesis that low dopaminergic neurotransmission is associated with detached personality.

Dopamine in schizophrenia: a review and reconceptualization.

The authors hypothesize that schizophrenia is characterized by abnormally low prefrontal dopamine activity leading to excessive dopamine activity in mesolimbic dopamine neurons (causing positive symptoms) and has important implications for treatment of schizophrenia and schizophrenia spectrum disorders.

Demonstration in vivo of reduced serotonin responsivity in the brain of untreated depressed patients.

This study provides the first direct visualization of blunted regional brain responses to serotonin release in the brain of patients with major depression, a finding that supports the hypothesis of impaired serotonergic transmission in depression.

Brain Dopamine Neurotoxicity in Baboons Treated with Doses of Methamphetamine Comparable to Those Recreationally Abused by Humans: Evidence from [11C]WIN-35,428 Positron Emission Tomography Studies and Direct In Vitro Determinations

The results indicate that methamphetamine, at doses used by some humans, produces long-term reductions in brain DA axonal markers in baboons, and that it is possible to detect methamphetamine-induced DAT loss in living nonhuman primates by means of PET.

Alterations in binding site density of dopamine transporter in the striatum, orbitofrontal cortex, and amygdala in early Parkinson's disease: Compartment analysis for β‐CFT binding with positron emission tomography

Results indicated that not only the striatal but also the orbitofrontal and amygdalar presynaptic dopaminergic functions were altered in early PD, which might contribute to the mental and behavioral impairment observed in PD.